<p>Ironwood Pharmaceuticals（納斯達克代碼：IRWD - 獲取免費報告）在週一發佈的研究報告中被 Citizens JMP 的分析師從 “跑贏大盤” 評級下調至 “市場表現” 評級，Briefing.com 自動導入報告。</p>
<p>其他一些股票研究分析師最近也對該公司發表了看法。StockNews.com 在 3 月 29 日的研究報告中將 Ironwood Pharmaceuticals 的股票評級從 “持有” 上調至 “買入”。Craig Hallum 在 1 月 22 日的研究報告中將 Ironwood Pharmaceuticals 的目標價格從 10.00 美元下調至 8.00 美元，並對該股票給予 “買入” 評級。最後，JMP Securities 在 1 月 30 日的研究報告中將 Ironwood Pharmaceuticals 的目標價格從 23.00 美元下調至 14.00 美元，並對該股票給予 “跑贏大盤” 評級。四位分析師對該股票給予 “持有” 評級，四位分析師則給予 “買入” 評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，共識目標價格為 8.60 美元。</p>
<p><strong>查看我們對 IRWD 的最新分析</strong></p>
<h2>Ironwood Pharmaceuticals 股價下跌 30.8%</h2>
<p>納斯達克：IRWD 週一下跌 0.29 美元，報 0.65 美元。該股票交易量為 7,159,342 股，而其平均交易量為 2,469,602 股。Ironwood Pharmaceuticals 的 52 周低點為 0.59 美元，52 周高點為 8.45 美元。該股票的 50 日移動平均線為 1.55 美元，200 日移動平均線為 3.12 美元。該股票的市值為 1.0592 億美元，市盈率為-21.82，貝塔值為 0.30。</p>
<p>Ironwood Pharmaceuticals（納斯達克代碼：IRWD - 獲取免費報告）於 2 月 27 日發佈了季度財報。這家生物技術公司報告該季度每股收益為 0.02 美元，低於分析師的共識預期 0.10 美元，差距為 0.08 美元。該公司該季度的收入為 9055 萬美元，而分析師預期為 9385 萬美元。Ironwood Pharmaceuticals 的淨利潤率為-0.65%，股本回報率為-0.96%。分析師預測 Ironwood Pharmaceuticals 在當前年度的每股收益將為 0.1 美元。</p>
<h2>內部買賣情況</h2>
<p>在其他新聞中，首席營銷官 Michael Shetzline 在 2 月 10 日的交易中出售了 41,269 股公司的股票。股票以平均價格 1.76 美元出售，總交易額為 72,633.44 美元。交易完成後，首席營銷官現在持有 554,007 股公司股票，價值約 975,052.32 美元。這筆交易代表其持股減少了 6.93%。該交易已在向證券交易委員會提交的文件中披露，您可以通過此鏈接訪問。此外，首席執行官 Thomas A. Mccourt 在 2 月 10 日的交易中出售了 139,064 股公司的股票。股票以平均價格 1.76 美元出售，總交易額為 244,752.64 美元。交易完成後，首席執行官現在持有 1,160,634 股公司的股票，價值 2,042,715.84 美元。這代表其持股減少了 10.70%。該交易的披露信息可以在這裏找到。在過去三個月中，內部人士出售了價值 338,591 美元的 192,381 股公司股票。公司內部人士持有 12.90% 的股票。</p>
<h2>Ironwood Pharmaceuticals 的機構交易</h2>
<p>大型投資者最近對該股票的持倉進行了調整。Point72 Asia Singapore Pte. Ltd.在第四季度購買了 Ironwood Pharmaceuticals 的新股份，價值約 36,000 美元。Journey Strategic Wealth LLC 在第四季度購買了 Ironwood Pharmaceuticals 的新股份，價值 45,000 美元。Catalyst Funds Management Pty Ltd 在第四季度獲得了 Ironwood Pharmaceuticals 的新持倉，價值 47,000 美元。Envestnet Asset Management Inc.在第四季度購買了 Ironwood Pharmaceuticals 的新持倉，價值 50,000 美元。最後，Xponance Inc.在第四季度獲得了 Ironwood Pharmaceuticals 的新持倉，價值 50,000 美元。</p>
<h2>關於 Ironwood Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Ironwood Pharmaceuticals, Inc.是一家醫療保健公司，專注於胃腸道（GI）產品的開發和商業化。它在美國、墨西哥、日本、沙特阿拉伯和中國以 LINZESS 的名稱銷售 linaclotide，這是一種用於治療患有便秘型腸易激綜合症或慢性特發性便秘的成人的鳥苷酸酰化酶 C（GC-C）激動劑，同時在加拿大和歐洲國家以 CONSTELLA 的名稱銷售。</p>
<h2>精選故事</h2>
<ul>
<li>我們更喜歡的五隻股票超過 Ironwood Pharmaceuticals</li>
<li>三隻值得購買和持有的醫療保健分紅股票</li>
<li>第一季度內部人士購買的三隻大盤股：買入、賣出或持有</li>
<li>投資於便士股票需要了解的事項</li>
<li>三隻在 2025 年市場低迷中逆勢而上的新 IPO</li>
<li>現在值得購買的兩隻金融科技股票和一隻需要避免的股票</li>
<li>三隻以折扣價交易的高收益分紅股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJXRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJXRA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Ironwood Pharmaceuticals 嗎？</h2>
<p>在考慮 Ironwood Pharmaceuticals 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Ironwood Pharmaceuticals 並不在名單上。</p>
<p>雖然 Ironwood 醫藥目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

Ironwood醫藥

<p>Citizens Jmp 在最近的一份報告中將 Ironwood Pharmaceuticals (NASDAQ:IRWD) 的評級從 “跑贏大盤” 下調至 “市場表現”。其他分析師的觀點不一，StockNews.com 將其評級上調至 “買入”，而 Craig Hallum 和 JMP Securities 則下調了目標價格。該股票經歷了顯著下跌，交易價格下跌 30.8% 至 0.65 美元，市值為 1.0592 億美元。最近的內部交易顯示首席醫學官和首席執行官出售了股份，機構投資者也在公司中增持了新股份。Ironwood 專注於胃腸道產品，特別是用於治療 IBS 的 linaclotide</p>

<p>Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) was downgraded by analysts at Citizens Jmp from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report issued on Monday,Briefing.com Automated Import reports.</p>
<div class="lb-trans"><p>Ironwood Pharmaceuticals（納斯達克代碼：IRWD - 獲取免費報告）在週一發佈的研究報告中被 Citizens JMP 的分析師從 “跑贏大盤” 評級下調至 “市場表現” 評級，Briefing.com 自動導入報告。</p>
</div><p>A number of other equities research analysts also recently weighed in on the company. StockNews.com upgraded shares of Ironwood Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, March 29th. Craig Hallum lowered their target price on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a &#34;buy&#34; rating on the stock in a research report on Wednesday, January 22nd. Finally, JMP Securities lowered their target price on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a &#34;market outperform&#34; rating on the stock in a research note on Thursday, January 30th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $8.60.</p>
<div class="lb-trans"><p>其他一些股票研究分析師最近也對該公司發表了看法。StockNews.com 在 3 月 29 日的研究報告中將 Ironwood Pharmaceuticals 的股票評級從 “持有” 上調至 “買入”。Craig Hallum 在 1 月 22 日的研究報告中將 Ironwood Pharmaceuticals 的目標價格從 10.00 美元下調至 8.00 美元，並對該股票給予 “買入” 評級。最後，JMP Securities 在 1 月 30 日的研究報告中將 Ironwood Pharmaceuticals 的目標價格從 23.00 美元下調至 14.00 美元，並對該股票給予 “跑贏大盤” 評級。四位分析師對該股票給予 “持有” 評級，四位分析師則給予 “買入” 評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，共識目標價格為 8.60 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on IRWD</strong></p>
<div class="lb-trans"><p><strong>查看我們對 IRWD 的最新分析</strong></p>
</div><h2>Ironwood Pharmaceuticals Trading Down 30.8 %</h2>
<div class="lb-trans"><h2>Ironwood Pharmaceuticals 股價下跌 30.8%</h2>
</div><p>NASDAQ:IRWD traded down $0.29 on Monday, hitting $0.65. 7,159,342 shares of the stock were exchanged, compared to its average volume of 2,469,602. Ironwood Pharmaceuticals has a fifty-two week low of $0.59 and a fifty-two week high of $8.45. The stock has a fifty day moving average of $1.55 and a 200-day moving average of $3.12. The stock has a market cap of $105.92 million, a PE ratio of -21.82 and a beta of 0.30.</p>
<div class="lb-trans"><p>納斯達克：IRWD 週一下跌 0.29 美元，報 0.65 美元。該股票交易量為 7,159,342 股，而其平均交易量為 2,469,602 股。Ironwood Pharmaceuticals 的 52 周低點為 0.59 美元，52 周高點為 8.45 美元。該股票的 50 日移動平均線為 1.55 美元，200 日移動平均線為 3.12 美元。該股票的市值為 1.0592 億美元，市盈率為-21.82，貝塔值為 0.30。</p>
</div><p>Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.08). The firm had revenue of $90.55 million for the quarter, compared to analyst estimates of $93.85 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. As a group, analysts predict that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current year.</p>
<div class="lb-trans"><p>Ironwood Pharmaceuticals（納斯達克代碼：IRWD - 獲取免費報告）於 2 月 27 日發佈了季度財報。這家生物技術公司報告該季度每股收益為 0.02 美元，低於分析師的共識預期 0.10 美元，差距為 0.08 美元。該公司該季度的收入為 9055 萬美元，而分析師預期為 9385 萬美元。Ironwood Pharmaceuticals 的淨利潤率為-0.65%，股本回報率為-0.96%。分析師預測 Ironwood Pharmaceuticals 在當前年度的每股收益將為 0.1 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣情況</h2>
</div><p>In other news, CMO Michael Shetzline sold 41,269 shares of the firm's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $72,633.44. Following the transaction, the chief marketing officer now owns 554,007 shares in the company, valued at approximately $975,052.32. This trade represents a 6.93 % decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, CEO Thomas A. Mccourt sold 139,064 shares of the company's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $244,752.64. Following the completion of the sale, the chief executive officer now owns 1,160,634 shares of the company's stock, valued at $2,042,715.84. This represents a 10.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 192,381 shares of company stock worth $338,591. 12.90% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他新聞中，首席營銷官 Michael Shetzline 在 2 月 10 日的交易中出售了 41,269 股公司的股票。股票以平均價格 1.76 美元出售，總交易額為 72,633.44 美元。交易完成後，首席營銷官現在持有 554,007 股公司股票，價值約 975,052.32 美元。這筆交易代表其持股減少了 6.93%。該交易已在向證券交易委員會提交的文件中披露，您可以通過此鏈接訪問。此外，首席執行官 Thomas A. Mccourt 在 2 月 10 日的交易中出售了 139,064 股公司的股票。股票以平均價格 1.76 美元出售，總交易額為 244,752.64 美元。交易完成後，首席執行官現在持有 1,160,634 股公司的股票，價值 2,042,715.84 美元。這代表其持股減少了 10.70%。該交易的披露信息可以在這裏找到。在過去三個月中，內部人士出售了價值 338,591 美元的 192,381 股公司股票。公司內部人士持有 12.90% 的股票。</p>
</div><h2>Institutional Trading of Ironwood Pharmaceuticals</h2>
<div class="lb-trans"><h2>Ironwood Pharmaceuticals 的機構交易</h2>
</div><p>Large investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in Ironwood Pharmaceuticals during the fourth quarter worth approximately $36,000. Journey Strategic Wealth LLC bought a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth $45,000. Catalyst Funds Management Pty Ltd acquired a new position in Ironwood Pharmaceuticals in the 4th quarter valued at $47,000. Envestnet Asset Management Inc. bought a new position in Ironwood Pharmaceuticals in the 4th quarter worth $50,000. Finally, Xponance Inc. acquired a new position in Ironwood Pharmaceuticals during the 4th quarter worth $50,000.</p>
<div class="lb-trans"><p>大型投資者最近對該股票的持倉進行了調整。Point72 Asia Singapore Pte. Ltd.在第四季度購買了 Ironwood Pharmaceuticals 的新股份，價值約 36,000 美元。Journey Strategic Wealth LLC 在第四季度購買了 Ironwood Pharmaceuticals 的新股份，價值 45,000 美元。Catalyst Funds Management Pty Ltd 在第四季度獲得了 Ironwood Pharmaceuticals 的新持倉，價值 47,000 美元。Envestnet Asset Management Inc.在第四季度購買了 Ironwood Pharmaceuticals 的新持倉，價值 50,000 美元。最後，Xponance Inc.在第四季度獲得了 Ironwood Pharmaceuticals 的新持倉，價值 50,000 美元。</p>
</div><h2>About Ironwood Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Ironwood Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.</p>
<div class="lb-trans"><p>Ironwood Pharmaceuticals, Inc.是一家醫療保健公司，專注於胃腸道（GI）產品的開發和商業化。它在美國、墨西哥、日本、沙特阿拉伯和中國以 LINZESS 的名稱銷售 linaclotide，這是一種用於治療患有便秘型腸易激綜合症或慢性特發性便秘的成人的鳥苷酸酰化酶 C（GC-C）激動劑，同時在加拿大和歐洲國家以 CONSTELLA 的名稱銷售。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Ironwood Pharmaceuticals</li>
<li>The Top 3 Healthcare Dividend Stocks to Buy and Hold</li>
<li>Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold</li>
<li>What to Know About Investing in Penny Stocks</li>
<li>3 Hot New IPOs Defying the 2025 Market Slump</li>
<li>2 Fintech Stocks to Buy Now and 1 to Avoid</li>
<li>3 High-Yield Dividend Stocks Trading at a Discount</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更喜歡的五隻股票超過 Ironwood Pharmaceuticals</li>
<li>三隻值得購買和持有的醫療保健分紅股票</li>
<li>第一季度內部人士購買的三隻大盤股：買入、賣出或持有</li>
<li>投資於便士股票需要了解的事項</li>
<li>三隻在 2025 年市場低迷中逆勢而上的新 IPO</li>
<li>現在值得購買的兩隻金融科技股票和一隻需要避免的股票</li>
<li>三隻以折扣價交易的高收益分紅股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJXRA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=IRWD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Ironwood Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Ironwood Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Ironwood Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Ironwood Pharmaceuticals 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ironwood Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Ironwood Pharmaceuticals 並不在名單上。</p>
</div><p>While Ironwood Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Ironwood 醫藥目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Ironwood Pharmaceuticals（納斯達克股票代碼：IRWD）的股票評級被 Citizens Jmp 下調